Bootstrapped, investor-backed or something in between: how real founders are building health startups and funding their ideas

You’ve got a great idea for a healthcare business – but how can you fund it? In an industry where clinical credibility must align with commercial viability, the route to capital rarely follows a straight line.

Some founders start by funding their ventures themselves. Others jump straight into investor-backed growth. Increasingly, many are blending self-funding with strategic capital injections, trying to balance control, validation, and momentum.

The bootstrapped advantage

Bootstrapping – using personal savings or early revenues to fund operations – remains a viable path, especially for less capital-intensive digital health models.

Updoc provides an example. The telehealth platform launched in 2021 and initially grew entirely without external funding. Bootstrapped for its first 3 years, Updoc served over 200,000 clients before securing $20 million from Bailador Technology Investments to scale technology and expansion efforts.

Advantages of bootstrapping:

• Maintains full ownership and decision-making autonomy
• Avoids early dilution when valuations are still low
• Enables agile pivoting without board approvals.

Trade-offs:

• Growth may be slower
• Marketing and hiring may be constrained
• Not always viable in capital-heavy sectors like medtech or biotech.

Investor-backed from day one

For founders in clinical trials, advanced tech or regulatory-heavy fields, venture or angel investment from the outset may be essential.

One example of investor-backed growth from inception is Everlab, a healthtech startup building a personalised longevity operating system. Founded in 2023, Everlab secured A$3 million in pre-seed funding – one of the largest raises of its kind in Australia. This early capital enabled Everlab to launch with immediate traction, assembling a cross-functional team and fast-tracking product development. Aligning with investors who understood the long-term potential of preventive and personalised healthcare gave Everlab both the resources and strategic support to scale from day one.

Advantages of early-stage funding:

• Accelerates product development
• Facilitates hiring of top talent
• Provides a runway to scale rapidly.

Considerations:

• Introduces investor expectations and board oversight
• Often shifts growth metrics and business direction toward aggressive targets.

The hybrid approach: something in between

Combining self-funding with strategic capital injections allows founders to validate their model before diluting equity, potentially yielding better terms and control later.

Cubiko is a strong example of a hybrid funding model. The practice intelligence software business began inside Inala Primary Care in Brisbane and developed without external capital in its earliest stages. In 2020, Cubiko raised $475,000 through a family-and-friends round and backing from Queensland’s Business Development Fund. One of the lead investors was prominent GP, Dr John Aloizos AM, who brought both capital and healthcare insight to the table.

As Cubiko grew, it secured a second seed round of $1.7 million in 2021, supported by angel investors, including ACAC Innovation and Aginic Ventures. The combined funding allowed Cubiko to accelerate growth while maintaining control during its formative years. It reinvested revenue, built its analytics platform, and expanded to over 300 practices, all without the pressure of large-scale venture capital.

Hybrid strategies often include:

• Friends-and-family seed funding for MVP testing
• Non-dilutive options like R&D tax incentives or grants
• Early angel rounds combined with reinvested revenues
• Debt financing to preserve equity while covering working capital.

Funding realities for healthcare startups

Healthcare entrepreneurs face distinct funding challenges, including:

• Substantial regulatory compliance costs (AHPRA, TGA, clinical trials etc)
• Extended health systems and procurement cycles which can slow cash flow
• Need for clinical credibility – investors expect validation, advisory boards and research partnerships
• Multiple stakeholders such as patients, clinicians and funders whose needs must all be met simultaneously.

These factors underscore the importance of strategic financial planning from day one.

How to choose your funding path

1. Assess your capital intensity

Can you start with low capital? If yes, bootstrapping may offer time to refine your model before raising externally.

2. Map your growth horizon

Are you aiming for rapid scale or steady specialist service growth? Each path has very different timelines and funding needs.

3. Understand your control vs speed tolerance

External funding may fast-track growth but often shifts your role from hands-on founder to investor-accountable CEO. Work out where your sweet spot is.

4. Leverage non-dilutive sources first

Grants, accelerators and early customer revenues can reduce reliance on equity funding.

What matters most

There’s no one-size-fits-all in healthcare funding. Bootstrapping offers control, investor capital enables speed, and hybrid models can offer the best of both.

What counts most is clarity – knowing your market, funding requirements, how much risk you’re willing to accept or how much control you’re willing to cede.

The ideal funding path gives you the resources to build a sustainable, growing healthcare business while staying true to your original vision.

Here’s to your success!